Yeast‑Made M2 Nanoparticle Vaccine Protects Mice From Multiple Flu Strains

Overview

• Researchers at the University of Michigan presented results on Aug. 24 showing a preclinical vaccine made in baker’s yeast prompted protective immune responses in mice.
• The team engineered yeast to produce virus‑like particles that densely display the influenza A M2 protein, a surface protein that changes far less than the usual vaccine target hemagglutinin.
• Eighteen vaccinated mice developed antibodies that recognized M2 from five influenza strains and the vaccinated group showed 100% protection when challenged with three different strains.
• The university has licensed the technology to Esperovax to pursue development of an oral vaccine, while researchers say next steps include measuring how long protection lasts in animals and completing safety and regulatory work before human trials.
• The yeast platform could cut production time to about one month versus roughly six months for egg‑based methods and offer faster updates in a pandemic, but major unknowns remain about durability of immunity and how well mouse results will translate to people.